Life Science REIT will target a £300m raise when it floats on the AIM market of the London Stock Exchange next month, becoming the first London-listed real estate investment trust (REIT) focused on UK life science properties, with a £445m pipeline of projects.
The company will launch an IPO on AIM by way of a placing, offer for subscription and intermediaries offer, targeting the issue of 300 million ordinary shares of £0.01 each in the capital of the company, at an issue price of 100p per share, with admission expected in mid-November. Ironstone Asset Management has been appointed its investment adviser, with a management team led by Simon Farnsworth, some of the members of which have committed to invest around £3m in the issue. BMO postpones REIT IPO as sector challenges cause volatility Investors in Life Science REIT will have exposur...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
